3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
20
Not yet recruiting
3
Completed
3
Terminated
2
Enrolling by invitation
2
Active not recruiting
2
Suspended
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
129
Breast Neoplasms
113
Neoplasms
97
Neoplasm Metastasis
78
Melanoma
73
Leukemia, Myeloid, Acute
69
Colorectal Neoplasms
69
Prostatic Neoplasms
60
Multiple Myeloma
52
Lung Neoplasms
52
Ovarian Neoplasms
51
Squamous Cell Carcinoma of Head and Neck
46
Triple Negative Breast Neoplasms
42
Recurrence
41
Carcinoma, Renal Cell
39
Carcinoma, Hepatocellular
39
Pancreatic Neoplasms
36
Myelodysplastic Syndromes
36
Glioblastoma
35
Brain Neoplasms
34
Lymphoma
31
Stomach Neoplasms
30
Lymphoma, Non-Hodgkin
30
Endometrial Neoplasms
30
Leukemia
29
Lymphoma, Large B-Cell, Diffuse
28
Head and Neck Neoplasms
28
Uterine Cervical Neoplasms
26
Cholangiocarcinoma
26
Urinary Bladder Neoplasms
24
Interventions
abelacimab
2
MAA868
2
apixaban
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Venous Thromboembolism
×
1 year
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled